Calibr progresses innovative ideas from the interface between academia and pharma into paradigm changing medicines through exceptional collaborations and partnerships:
In 2012 Merck funded Calibr with up to $90 million over a period of seven years. Merck has an option to obtain an exclusive commercial license to any proteins or small molecule therapeutic candidates derived from work conducted by Calibr. For any projects not licensed by Merck, Calibr is free to seek alternative sources of funding for further development. In addition, Calibr accesses funds from government and non-government sources. More information about the Calibr-Merck can be found here.
Bill & Melinda Gates Foundation
The Gates Foundation provides grant funding to develop an “integrated drug discovery platform for diseases of the developing world” within Calibr with the goal to identify innovative new therapeutics for the treatment of diseases in the developing world such as helminth infections, malaria, tuberculosis, diarrheal diseases, HIV and Ebola.
Bristol-Myers Squibb and Calibr have entered into a worldwide research collaboration and license agreement focused to develop new treatment approaches for fibrotic diseases. More information on the partnership can be found here.
Calibr received a Translation Award in 2014 to develop a novel semi-synthetic antibody-based immunotherapy to treat hormone-refractory prostate cancer. The award provides complete support to progress a novel therapeutic agent to investigational new drug status ready for a Phase 1 clinical trial.
JDRF has provided significant funding in order to leverage Calibr’s unique high-throughput screening and biologics platforms to pursue novel therapeutics to treat diabetes. In total, Calibr has received seven awards from the JDRF since mid-2012 that fund activities from high-throughput screening, medicinal chemistry and proof-of-concept in vivo studies.
Calibr is working in collaboration with the TB Alliance to develop new drugs to treat tuberculosis, with a focus on developing new TB drugs with novel mechanisms of action that specifically target persistent and/or drug resistant stages of the disease.
There are currently no approved treatments for SMA. Drug discovery efforts are critical to move treatment beyond symptom management. Cure SMA provides funding to develop drugs that target novel mechanisms of action to treat spinal muscular atrophy.
The Lustgarten Foundation is currently providing funding for the development of small molecule inhibitors of a pancreatic cancer-specific enzyme to manipulate cancer metabolism as a means to cure the disease.
In late 2015, Pfizer and Calibr entered into a strategic collaboration to advance a long-acting biotherapeutic for chronic heart failure into first-in-human studies. Under the terms of the agreement, Pfizer obtained an exclusive option to license the program after Calibr performs Phase 1 studies in healthy volunteers and heart failure patients. More information on the partnership can be found here.